Gilead achieved surprising experimental results with an AIDS prevention drug
2024-06-20 23:04:43
On June 21st, local time on June 20th, Gilead Sciences (GILD. O), an American biopharmaceutical company, announced on its official website that its "Lenacapavir" (lenacapavir) has shown 100% effectiveness in preventing HIV. The latest published results are a phase 3 double-blind randomized trial called "PURPOSE 1", which aimed to evaluate the safety and efficacy of Lenacapavir and Descovy in more than 5,300 women aged 16-25 at 25 sites in South Africa and 3 sites in Uganda. The results showed that among the 2,134 women in the Lenacapavir group, there were 0 cases of HIV infection.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
